Vector-borne diseases (VBDs) represent a significant public health challenge in India, with increasing incidence and geographical spread.
India bears a high burden of VBDs, including malaria, dengue, and chikungunya, which are associated with high morbidity and mortality. Climate change, urbanization, and inadequate vector control are key contributing factors.
The healthcare system's response includes early detection, prompt treatment, and integrated vector management. However, challenges persist due to resource constraints and gaps in surveillance.
Healthcare professionals play a crucial role in managing VBDs, from clinical management to public health advocacy. Their active participation is needed to enhance disease surveillance, patient education, and community engagement.
Addressing the escalating challenge of VBDs in India requires a multifaceted approach, involving healthcare professionals, policy-makers, and communities. Strengthening the healthcare system's response and enhancing professional capacity are key to mitigating this public health threat.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation